AXL is a potential therapeutic target in dedifferentiated and pleomorphic liposarcomas

BACKGROUND: AXL is a well-characterized, protumorigenic receptor tyrosine kinase that is highly expressed and activated in numerous human carcinomas and sarcomas, including aggressive subtypes of liposarcoma. However, the role of AXL in the pathogenesis of well-differentiated (WDLPS), dedifferentiat...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:BMC Cancer
Autors principals: May, Caitlin D., Garnett, Jeannine, Ma, XiaoYan, Landers, Sharon M., Ingram, Davis R., Demicco, Elizabeth G., Al Sannaa, Ghadah A., Vu, Tona, Han, Lixia, Zhang, Yi, Kivlin, Christine M., Bolshakov, Svetlana, Kalam, Azad Abul, Liu, Juehui, Zhou, Fuguo, Broccoli, Dominique, Wang, Wei-Lien, Lazar, Alexander J., Pollock, Raphael E., Lev, Dina, Torres, Keila E.
Format: Artigo
Idioma:Inglês
Publicat: BioMed Central 2015
Matèries:
Research Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4647521/
https://ncbi.nlm.nih.gov/pubmed/26573603
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-015-1916-3
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars